Pongpak Pongphitcha

Pongpak Pongphitcha

Auto-generated profile, based on publicly available information

Pongpak Pongphitcha

Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University Bangkok Thailand

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NSNilubon Singhto
Nilubon Singhto
PPPongpak Pongphitcha
Pongpak Pongphitcha
NJNatini Jinawath
Natini Jinawath
SHSuradej Hongeng
Suradej Hongeng
SCSomchai Chutipongtanate
Somchai Chutipongtanate
Liquid biopsy involves the utilization of minimally invasive or noninvasive techniques to detect biomarkers in biofluids for disease diagnosis, monitoring, or guiding treatments. This approach is promising for the early diagnosis of childhood cancer, especially for brain tumors, where tissue biopsies are more challenging and cause late detection. Extracellular vesicles offer several characteristics that make them ideal resources for childhood cancer liquid biopsy. Extracellular vesicles are nanosized particles, primarily secreted by all cell types into body fluids such as blood and urine, and contain molecular cargos, i.e., lipids, proteins, and nucleic acids of original cells. Notably, the lipid bilayer-enclosed structure of extracellular vesicles protects their cargos from enzymatic degradation in the extracellular milieu. Proteins and nucleic acids of extracellular vesicles represent genetic alterations and molecular profiles of childhood cancer, thus serving as promising resources for precision medicine in cancer diagnosis, treatment monitoring, and prognosis prediction. This review evaluates the recent progress of extracellular vesicles as a liquid biopsy platform for various types of childhood cancer, discusses the mechanistic roles of molecular cargos in carcinogenesis and metastasis, and provides perspectives on extracellular vesicle-guided therapeutic intervention. Extracellular vesicle-based liquid biopsy for childhood cancer may ultimately contribute to improving patient outcomes.

13 May 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
KSKunanya Suwannaying
Kunanya Suwannaying
CMChalinee Monsereenusorn
Chalinee Monsereenusorn
PRPiya Rujkijyanont
Piya Rujkijyanont
PTPiti Techavichit
Piti Techavichit
KPKamon Phuakpet
Kamon Phuakpet
TGThai Pediatric Oncology Neuroblastoma Working Group
Thai Pediatric Oncology Neuroblastoma Working Group

2 October 2024 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
NTNonthaya Thangrua
Nonthaya Thangrua
TSTeerapong Siriboonpiputtana
Teerapong Siriboonpiputtana
BRBudsaba Rerkamnuaychoke
Budsaba Rerkamnuaychoke
TCTakol Chareonsirisuthigul
Takol Chareonsirisuthigul
VKVeerawat Korkiatsakul
Veerawat Korkiatsakul
SPSamart Pakakasama
Samart Pakakasama

8 April 2025 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
ASAnusak Sakwit
Anusak Sakwit
PPPongpak Pongphitcha
Pongpak Pongphitcha
PKPatcharee Komvilaisak
Patcharee Komvilaisak
MOMasayuki Ochiai
Masayuki Ochiai
DTDaijiro Takahashi
Daijiro Takahashi
NSNongnuch Sirachainan
Nongnuch Sirachainan
Vitamin K deficiency (VKD) in cholestatic liver disease affects up to 23% of pediatric patients. While several vitamin K (VK) prophylaxis regimens have been proposed, optimal therapeutic strategies remain undefined. The study aimed to identify the most effective VK prophylaxis for children with cholestatic liver disease. We conducted a systematic review of articles focusing on studies of children aged <18 years with cholestatic liver disease who reported outcomes of either VKD or vitamin K deficiency bleeding (VKDB) after VK prophylaxis. The articles were sourced from PubMed, Scopus, and Embase. A meta-analysis was performed to determine the prevalence of VKD and the efficacy of each prophylactic protocol in preventing VKD/VKDB. The study was registered on PROSPERO (CRD 42021270048). Of the 889 articles, 37 were selected (2 comparative studies, 6 noncomparative studies, and 29 case reports/series). The results from the comparative studies indicated a lower incidence of VKD in the parenteral than that in the oral VK. The meta-analysis of the noncomparative studies showed the prevalence of VKD in high prothrombin induced by vitamin K absence-II group was 56% (95% CI, 45%-68%; I2 = 0.0%; H2 = 1.0; Q test: χ2 = 1.93; P = .38) and a prevalence of VKD in abnormal coagulation test was 10% (95% CI, 5%-14%; I2 = 0%, H2 = 1.0; Q test: χ2 = 0.82; P = .66), respectively. Among the 3 administrative routes, the analysis from case reports/series showed the median onset of VKDB in cholestatic infants was the earliest in the oral (44.5 days; IQR, 13.0-240.0 days) compared with intramuscular (86.0 days; IQR, 36.0-120.0) and intravenous routes and intravenous (97.0 days; IQR, 74.0-120.0 days) VK prophylaxis. Available studies to determine the optimal route of VK administration in children with cholestatic liver disease were limited. The result from the review indicated that parenteral VK demonstrated a noticeable advantage over oral VK for VKD/VKDB prevention in cholestatic children.

26 October 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
RURawinun Udomponglukkana
Rawinun Udomponglukkana
WSWerasak Bsc Sasanakul
Werasak Bsc Sasanakul
NTNoppawan Msc Tangbubpha
Noppawan Msc Tangbubpha
ACAmpaiwan Chuansumrit
Ampaiwan Chuansumrit
TTThipwimol Tim-Aroon
Thipwimol Tim-Aroon
NSNongnuch Sirachainan
Nongnuch Sirachainan
Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder caused by mutations in the TMPRSS6 gene, which impair iron homeostasis. We reported a 4-year-old girl who presented with a 1-year history of iron deficiency anemia. Her hemoglobin level increased from 6.5 g/dL to 12.6 g/dL with a prolonged duration of therapeutic dose oral iron therapy (5 mg/kg/d), and the level remained quite stable during the therapy. Genetic analysis of the TMPRSS6 gene revealed compound heterozygotes of 2 novel pathogenic variants: c.811C> T (NM_153609.3) in exon 7 (NP_705837: p.R271Ter) and c.1254C> G in exon 11 (p.Y418Ter). The results highlight the significance of genetic investigation and long-term iron therapy in iron-refractory iron deficiency anemia patients.

23 May 2024 in Haemophilia
Verified
Journal Article
Closed access
PPPongpak Pongphitcha
Pongpak Pongphitcha
WSWerasak Sasanakul
Werasak Sasanakul
PKPraguywan Kadegasem
Praguywan Kadegasem
DSDuantida Songdej
Duantida Songdej
CLChanin Limwongse
Chanin Limwongse
NSNongnuch Sirachainan
Nongnuch Sirachainan